Background
Biomarker | Target | Advantages | Disadvantages |
---|---|---|---|
Volumetry (vMRI) | Whole brain/medial temporal lobe, hippocampus | Highly reproducible and sensitive to disease-related changes | Late-stage biomarker; cannot provide information on the cause of atrophy |
Cortical thickness | Cerebral cortex | May improve classification between dementia subtypes | Limited to neocortex; cannot be used to determine the cause of atrophy |
Functional MRI (fMRI) | Regional/network functional activity | Can evaluate robusticity of networks at resting state and during tasks | Reproducibility and influence of vasculature unclear |
FLAIR/T2 imaging | White matter lesions | Highly sensitive | Cannot determine the cause of the lesion |
T2*/susceptibility-weighted imaging | Microbleeds/myelin/iron | Microbleed location can aid diagnosis | Undesirable artifacts at air/tissue interfaces; few longitudinal studies to date |
Diffusion tensor imaging | White matter | Highly sensitive to white matter damage | Fairly low resolution and sensitive to artifacts from water diffusion; particularly sensitive to movements |
Neuromelanin-sensitive | Locus coeruleus, substantia nigra | Sensitive to noradrenergic and dopaminergic subcortical nuclei | Semi-quantitative assessment/not disease specific |
Biomarker | Target | Advantages | Disadvantages |
---|---|---|---|
18F-FDG | Glucose metabolism | Capable of detecting dysfunction that has not necessarily involved atrophy; well-validated for clinical research | Variability in methods of analysis between studies/centers |
18F-FDDNP | AD lesions | 18F half-life does not require on-site cyclotron | Does not differentiate Aβ or tau aggregations |
11C-PBB3 | Tau lesions | Sensitive to both AD-type tau aggregations and non-AD tau aggregations; correlates with clinical progression | Short half-life of 11C; relatively low affinity compared to other tau markers; non-specific binding |
18F-AV1451 (flortaucipir) | Tau lesions | High affinity to aggregated tau; distribution of binding reflects clinical presentations; 18F half-life does not require on-site cyclotron | Off-target binding to neuromelanin and choroid plexus; poor reliability in early NFT stages; preferential binding to mixed 3R/4R tau rather than isolated 3R or 4R tau |
18F-GTP1 | Tau lesions | Ligand binding maps to known distribution of AD-tau aggregations; 18F half-life does not require on-site cyclotron | Yet to be fully validated; possible high non-specific binding in basal ganglia |
18F-MK6240 | Tau lesions | Extremely high binding affinity to tau aggregations; good brain delivery and washout; 18F half-life does not require on-site cyclotron | Likely preferential binding to mixed 3R/4R tau rather than isolated 3R or 4R tau; off-target binding to neuromelanin |
18F-RO6958948 | Tau lesions | High binding affinity to tau aggregations; preliminary study shows longitudinal increases in AD; 18F half-life does not require on-site cyclotron | Yet to be fully validated; no significant binding in 3R or 4R tauopathies |
18F-THK5351 | Tau lesions | High binding affinity to tau over Aβ aggregations; 18F half-life does not require on-site cyclotron | High non-specific retention in the subcortical white matter; high MOA-B binding |
18F-THK5105 | Tau lesions | High binding affinity to tau over Aβ aggregations; 18F half-life does not require on-site cyclotron | High non-specific retention in the subcortical white matter; inferior signal-to-background ratio |
18F-THK523 | Tau lesions | High binding affinity to tau over Aβ aggregations; 18F half-life does not require on-site cyclotron | High non-specific retention in the subcortical white matter; poor in vivo visualization of tau deposition |
18F-PI2620 | Tau lesions | Binds to both 3R/4R mix tau and 3R tau (Pick’s disease); high binding affinity to tau over Aβ aggregations and MOA-A/MOA-B; 18F half-life does not require on-site cyclotron | Yet to be fully validated |
18F-PM-PBB3 | Tau lesions | Indication that ligand is sensitive to both AD and non-AD tauopathies; little binding to MOA-A and MOA-B; 18F half-life does not require on-site cyclotron | Yet to be fully validated, particularly in non-AD tauopathies |
11C-PiB | Amyloid-β aggregations | High affinity to fibrillar Aβ; best studied of available Aβ PET tracers | Short half-life of 11C; not specific to AD amyloidosis/binds to CAA |
18F-AV-45 | Amyloid-β aggregations | High affinity to fibrillar Aβ; 18F half-life does not require on-site cyclotron | Not specific to AD amyloidosis |
18F-BAY94-9172 (florbetaben) | Amyloid-β aggregations | High affinity to fibrillar Aβ; 18F half-life does not require on-site cyclotron | Not specific to AD amyloidosis |
18F-GE067 (flutemetamol) | Amyloid-β aggregations | High affinity to fibrillar Aβ; 18F half-life does not require on-site cyclotron | Not specific to AD amyloidosis |
18F-NAV4694 | Amyloid-β aggregations | Excellent agreement with 11C-PiB; 18F half-life does not require on-site cyclotron | Not specific to AD amyloidosis |
11C-UCB-J | Synapses (SV2A) | High affinity to protein expressed on synapses | Short half-life of 11C; relatively new tracer and not well-validated in dementia populations |
Biomarker | Target | Advantages | Disadvantages |
---|---|---|---|
Aβ42 | Amyloid-β peptides | Strong correlation with 11C-PiB PET status | Different cutoff values used in different labs |
Aβ40 | Amyloid-β peptides | Added value when combined with Aβ42 | Not a clinically meaningful biomarker in isolation |
Aβ42/Aβ40 ratio | Amyloid-β peptides | Stronger diagnostic and prognostic value than Aβ42 alone | Not yet widely implemented |
Aβ42/Aβ38 ratio | Amyloid-β peptides | Stronger diagnostic and prognostic value than Aβ42 alone | Not yet widely implemented |
t-Tau | Tau peptides | Reasonably sensitive for late-stage AD | Poor specificity, not clinically useful in isolation |
p-Thr181 tau | Tau peptides | Reasonably sensitive for late-stage AD | Poor specificity, not clinically useful in isolation |
NfL | White matter damage | Indicates the presence of neurodegeneration | Increased in multiple neurodegenerative diseases |
Biomarker | Target | Advantages | Disadvantages |
---|---|---|---|
Aβ42/Aβ40 ratio | Amyloid-β peptides | Automated platform available for measurements | Difference in values between disease groups too small to be used as a diagnostic tool. Levels can be affected by pattern change from monomer to protofibrils in blood. |
MDS-OAβ | Amyloid-β oligomers | Differentiates AD patients from HC with high sensitivity and specificity, not affected by pattern change in the blood | Poorly validated and limited availability of technology relative to ELISA-based methods |
IIR assay | Amyloid α-helix versus β-sheet form | Detects biophysical properties of pathologic forms of amyloid instead of just concentrations | Poorly validated and limited availability of technology relative to ELISA-based methods |
p-Thr181 tau | Tau peptides | Can accurately predict 11C-PiB PET status | Does not differentiate between tauopathies other than AD |
t-Tau | Tau peptides | Automated platform available for measurements | Large overlap between diagnostic groups |
NfL | White matter damage | Indicates the presence of neurodegeneration; strong correlation with CSF NfL | Increased in multiple neurodegenerative diseases |
Disease fundamentals
Alzheimer’s disease
Gene | Protein | Associated Syndrome(s) | Reference |
---|---|---|---|
APP | Amyloid precursor protein | EOAD (familial), CAA | Tanzi et al., 1987 [15] |
PSEN1 | Presenilin 1 | EOAD (familial) | Sherrington et al., 1995 [16] |
PSEN2 | Presenilin 2 | EOAD (familial) | Levy-Lahad et al., 1995 [17] |
MAPT | MAPT | bvFTD, PSP | |
C9orf72 | C9orf72 | bvFTD, ALS | Renton et al., 2011 [20] |
GRN | Progranulin | bvFTD, CBS | Gass et al., 2006 [21] |
VCP | Valosin-containing protein | ALS | Johnson et al., 2010 [22] |
TARDBP | TDP-43 | ALS | Shreedharan et al., 2008 [23] |
SOD1 | Superoxide dismutase 1 | ALS | Rosen et al., 1993 [24] |
FUS | Fused-in sarcoma | ALS | |
HTT | Huntingtin | HD | HDCRG, 1993 [27] |
SNCA | α-synuclein | PD, DLB, MSA | Kruger et al., 1998 [28] |
GBA | β-glucocerebrosidase | PD, DLB, Gaucher | Sidransky and Lopez, 2012 [29] |
PRNP | Prion protein | Prion | |
ApoE (ε4 allele) | Apolioporotein-E | AD (risk factor) | |
TREM2 | TREM2 | AD (risk factor) |